Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news


From To
Inactive Ingredients in Medications Cause Trouble for Some

Most approved medications have inactive ingredients that could cause problems for individuals with allergies or intolerances to those ingredients, researchers say. Those problems can add up when patients take more than one medication with troublesome ingredients.

14 March 2019
Medscape (requires free registration)
Large French study examines neuropsychiatric side effects with integrase inhibitors

The largest prospective study to date on integrase inhibitors and their potential for being associated with neuropsychiatric side effects was conducted in France. With more than 21,000 HIV-positive participants, the study found that the proportion of people who stopped taking integrase inhibitors due to neuropsychiatric side effects was generally very low (between 1% and 3%). Of particular note is the fact that before starting treatment with an integrase-inhibitor-containing regimen, between 3% and 10% of participants had previously reported neuropsychiatric side effects with other classes of HIV treatment.

12 March 2019
Efavirenz and psychological performance in children living with HIV

Efavirenz remains a clinically effective and relevant antiretroviral drug for people living with HIV – but adverse side effects need to be screened for and monitored in children.

15 February 2019
Tenofovir Alafenamide Linked to Fanconi Syndrome

This case study is presented as a caution to clinicians that tenofovir alafenamide can cause Franconi Syndrome.

12 February 2019
Infectious Disease Advisor
South Africa urgently needs an antiretroviral pregnancy registry

With the dolutegravir roll-out around the corner, the time is now ripe for patients and activists to demand a prospective pregnancy registry for the whole of South Africa. Whether it is a new endeavour or piggy-backs on international efforts is a matter for debate, but it is the only way we can answer the question of dolutegravir’s safety with the minimum number of women being exposed to the drug. It’s the least that patients deserve.

29 January 2019
Six advantages of dolutegravir

Dolutegravir is a critically important antiretroviral medicine that is set to become the backbone of South Africa and many other countries’ HIV programmes. While the drug has recently made headlines because of a potential safety risk, most of what we know about the medicine indicates that it represents an important improvement over existing medicines.

28 January 2019
Spotlight SA
South Africa: New safety concerns emerge on latest HIV wonder drug

New safety concerns have emerged about the HIV drug dolutegravir, which the government plans to roll out in April.

18 January 2019
Business Day
Sleep Abnormalities Do Not Reverse After Discontinuing Efavirenz

For patients with HIV receiving efavirenz-based therapy, sleep and neuropsychological abnormalities do not readily reverse after discontinuation of treatment, according to results published in HIV Clinical Trials.

14 January 2019
Infectious Disease Advisor
Top 10 HIV Clinical Developments of 2018

It's the beginning of the end. Not in some apocalyptic way, but rather in how we think about the prevention and management of HIV.

20 December 2018
The Body Pro
What triggered my heart attack?

Jackie Morton, ex-Chair of the European AIDS Treatment Group, found her severe pain was due to a heart attack. Here she writes a detailed, dispassionate and scientific blog on the possible causes - and remedies.

19 November 2018
← First12345...17Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.